» Articles » PMID: 4022342

Plasmapheresis and Acute Guillain-Barré Syndrome. The Guillain-Barré Syndrome Study Group

Overview
Journal Neurology
Specialty Neurology
Date 1985 Aug 1
PMID 4022342
Citations 109
Affiliations
Soon will be listed here.
Abstract

We compared plasmapheresis with conventional therapy in 245 patients with the Guillain-Barré syndrome of recent onset. Statistically significant differences, favoring the plasmapheresis group, were found in terms of improvement at 4 weeks, time to improve one clinical grade, time to independent walking, and outcome at 6 months. Plasmapheresis was not effective for all patients, but was particularly effective for patients who received this treatment within 7 days of onset and for patients who required mechanical ventilation after entry into the study. Plasmapheresis appears to be of benefit in patients with Guillain-Barré syndrome of recent onset.

Citing Articles

Guillain-Barre syndrome following Pfizer-BioNTech (BNT162b2) vaccination: a case report.

Chaudhary A, Khadka S, Dulal A, Adhikari R, Bhardwaj S, Pandey A Ann Med Surg (Lond). 2024; 86(11):6693-6695.

PMID: 39525760 PMC: 11543217. DOI: 10.1097/MS9.0000000000002197.


Clinical presentation and symptomatology of Guillain-Barré syndrome: A literature review.

Elendu C, Osamuyi E, Afolayan I, Opara N, Chinedu-Anunaso N, Okoro C Medicine (Baltimore). 2024; 103(30):e38890.

PMID: 39058828 PMC: 11272278. DOI: 10.1097/MD.0000000000038890.


Guillain-Barré syndrome: History, pathogenesis, treatment, and future directions.

Hughes R Eur J Neurol. 2024; 31(11):e16346.

PMID: 38752584 PMC: 11464409. DOI: 10.1111/ene.16346.


Treatment Efficacy of Plasmapheresis Versus Intravenous Immunoglobulin in Guillain-Barré Syndrome Management: A Systematic Review.

Savithri Nandeesha S, Kasagga A, Hawrami C, Ricci E, Hailu K, Salib K Cureus. 2024; 16(3):e57066.

PMID: 38681292 PMC: 11052558. DOI: 10.7759/cureus.57066.


Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

Bus S, de Haan R, Vermeulen M, van Schaik I, Eftimov F Cochrane Database Syst Rev. 2024; 2:CD001797.

PMID: 38353301 PMC: 10865446. DOI: 10.1002/14651858.CD001797.pub4.